← Back to Clinical Trials
Recruiting NCT07086599

NCT07086599 Typological Study of Sleep Pathologies During Psoriatic Rheumatism and SAPHO Syndrome: Prospective Study Within the Paris Saint-Joseph Hospital Group"

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07086599
Status Recruiting
Phase
Sponsor Fondation Hôpital Saint-Joseph
Condition Psoriasis Arthritis
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2023-11-13
Primary Completion 2027-05-13

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2023-11-13 with a primary completion date of 2027-05-13.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Chronic inflammatory rheumatisms (CIR) are a source of motor disability and various comorbidities, particularly cardiovascular and metabolic. They also significantly impact patients' quality of life, including sleep disturbances. Among CIRs, psoriatic arthritis is a chronic inflammatory arthropathy associated with psoriasis, typically seronegative for rheumatoid factor. This heterogeneous disease affects peripheral and/or axial joints and can include extra-articular manifestations such as uveitis and chronic inflammatory bowel diseases. Its prevalence is estimated between 0.3% and 1% in the general population. SAPHO syndrome, similar to psoriatic arthritis, is characterized by specific bone involvement with a hypertrophic tendency, often affecting the axial skeleton and the anterior thoracic wall. Pain and inflammation are closely linked to sleep quality, creating a vicious cycle where pain disrupts sleep and poor sleep amplifies pain perception. Analgesic treatments, such as opioids, can also cause nocturnal respiratory pathologies, further disrupting sleep. Inflammatory processes are regulated by sleep, influencing plasma concentrations of CRP, IL6, and TNF production. Patients with psoriatic arthritis or SAPHO syndrome share common risk factors with Obstructive Sleep Apnea Syndrome (OSAS), such as obesity, hypertension, and metabolic syndrome. Sleep disorders are common in the general population and likely underdiagnosed in these patients. Several studies suggest a link between sleep disorders and these rheumatic conditions, affecting quality of life and exacerbating symptoms. Questionnaires like the Epworth and Pichot scales provide a more precise evaluation of these symptoms. However, objective sleep exploration through polysomnography has never been conducted in these patients. In summary, CIRs, particularly psoriatic arthritis and SAPHO syndrome, significantly impact patients' quality of life and sleep, necessitating appropriate evaluation and management of associated sleep disorders.

Eligibility Criteria

Inclusion Criteria: * Patient aged 18 years or older * Patient diagnosed with psoriatic arthritis or SAPHO syndrome and followed at Paris Saint-Joseph Hospital * Patient presenting sleep disorders warranting hospitalization for further -investigation of these disorders * French-speaking patient * Patient who does not oppose participation in the research protocol Exclusion Criteria: * Patient already followed for a sleep disorder * Patient who underwent polysomnography in the last 2 years * End-of-life patient * Patient under guardianship or curatorship * Patient deprived of liberty * Patient under legal protection

Contact & Investigator

Central Contact

Juliette COURTIADE MAHLER

✉ jcourtiade@ghpsj.Fr

📞 +33144127963

Frequently Asked Questions

Who can join the NCT07086599 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Psoriasis Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07086599 currently recruiting?

Yes, NCT07086599 is actively recruiting participants. Contact the research team at jcourtiade@ghpsj.Fr for enrollment information.

Where is the NCT07086599 trial being conducted?

This trial is being conducted at Paris, France.

Who is sponsoring the NCT07086599 clinical trial?

NCT07086599 is sponsored by Fondation Hôpital Saint-Joseph. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology